论文部分内容阅读
目的评价以吡柔比星(THP)为主化疗方案治疗血液统恶性肿瘤90例疗效观察。方法对本院2000年10月～2005年10月住院血液系统恶性肿瘤患者90例,采用以THP为主化疗方案治疗,其中初治30例,复治60例。急性白血病60例,恶性淋巴瘤21例,多发性骨髓瘤9例。结果急性白血病中初治的完全缓解率(CR)达91.7%,复发和难治的CR为(15/39)38.5%,恶性淋巴瘤有效率71.5%,多发性骨髓瘤有效率67.8%。90例中总有效率80.0%。吡柔比星的主要不良反应是骨髓抑制,由此引起的感染、出血分别为30.2%、20.5%;其他非骨髓系统的反应,多可耐受,主要表现为肝功能的损害,发生率为20.8%,多为一过性的转氨酶升高。结论吡柔比星(THP)可作为一线药物与其他化学药物联合治疗对血液系统恶性肿瘤有较好的疗效,且不良反应轻微。
Objective To evaluate the efficacy of pirarubicin (THP) -mediated chemotherapy in the treatment of 90 hematologic malignancies. Methods Totally 90 patients with malignant hematological malignancies admitted to our hospital from October 2000 to October 2005 were treated with THP-based chemotherapy, of which 30 had initial treatment and 60 had re-treatment. 60 cases of acute leukemia, 21 cases of malignant lymphoma, 9 cases of multiple myeloma. Results The complete remission rate (CR) of initial treatment in acute leukemia was 91.7%, CR in relapsed and refractory cases was 38.5% (15/39), effective rate in malignant lymphoma was 71.5%, and that in multiple myeloma was 67.8%. 90 cases, the total efficiency of 80.0%. The main adverse reactions of pirarubicin were myelosuppression, resulting in infection and bleeding of 30.2% and 20.5%, respectively. The response of other non-myeloid systems was more tolerable, with the main manifestation being the impairment of liver function, the incidence rate was 20.8%, mostly transient transaminase increased. Conclusions Pirarubicin (THP) can be used as a first-line drug in combination with other chemotherapeutics to treat malignant hematological malignancies with mild adverse reactions.